Advertisement


Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

2023 ASCO Annual Meeting

Advertisement

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma and prior BTK inhibitor therapy. Responses were observed in patients with high-risk disease features, including blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations (Abstract 7514).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Nirav N. Shah: So mantle cell lymphoma is a disease that sort of is felt to be a relapsing remitting disease, which means that most patients are going to relapse in their lifetime. Now, while we have very, very good therapies for relapse mantle cell, which generally include covalent BTK inhibitors. For those patients who progress after covalent BTK inhibitors, options are limited. We have treatments like CAR T-cell therapy, but not all patients are healthy enough, fit enough, or are in an area where CAR T-cell therapy is accessible. So pirtobrutinib was studied as part of the BRUIN trial to look specifically at patients with B-cell malignancies. And the data being reported is looking at the cohort of patients with mantle cell lymphoma who received this drug in a relapsed refractory setting. Unlike other BTK inhibitors pirtobrutinib is a non-covalent reversible inhibitor showing that it has a different mechanism of action than the BTK inhibitors that are currently being used in the second line setting. As part of the BRUIN study, whether or not you had prior BTK exposure was not an exclusion, and so actually the majority of patients who received pirtobrutinib, 90 of them, actually had prior BTK exposure, which is an unmet need in mantle cell lymphoma. Despite seeing a different BTK inhibitor, first, the overall response rate with pirtobrutinib was 58% in this heavily pretreated group, which is really just exciting to have another oral agent be effective in that patient population. Not only was it effective, but there were also durable responses. And so now in this sort of two year long term follow-up, we know that the median duration of response for those patients who were responding to therapy was 18 months, and the median overall survival was nearly 2 years. This data actually led to this drug now being FDA approved and in this clinical setting and available, and part of that is because the safety profile that's demonstrated in the BRUIN study in this patient population was actually quite favorable. The toxicities were low and the traditional BTK toxicities, things like atrial fibrillation, hypertension, and bleeding were actually seen at very low rates, such that may occur actually in a general patient population. In conclusion, I think that pirtobrutinib represents a novel mechanism of action in inhibiting the BTK pathway and allowing patients that have failed other covalent BTK inhibitors to continue receiving an oral medication that has now shown incredible efficacy, safety, and durability.

Related Videos

Leukemia

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavily treated patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Manufacturing CD5 CAR T cells with tyrosine kinase inhibitors seemed to improve their potency and antitumor activity (Abstract 7002).

Lung Cancer

Penelope Bradbury, MBChB, on Pleural Mesothelioma: New Results From the IND227 Trial of Cisplatin and Pemetrexed With or Without Pembrolizumab

Penelope Bradbury, MBChB, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with treatment-naive unresectable pleural mesothelioma, cisplatin and pemetrexed with pembrolizumab improved median overall survival with acceptable tolerability (Abstract LBA8505).

Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings showing that for patients with advanced or metastatic urothelial carcinoma and FGFR alteration who already had been treated with a PD-(L)1 inhibitor, erdafitinib significantly improved overall and progression-free survival, as well as overall response rate, compared with investigator’s choice of chemotherapy (LBA4619).

Lung Cancer

James Chih-Hsin Yang, MD, PhD, on Metastatic Nonsquamous NSCLC: Evaluating Pemetrexed and Platinum With or Without Pembrolizumab

James Chih-Hsin Yang, MD, PhD, of the National Taiwan University Hospital and National Taiwan University Cancer Center, discusses the latest data from the phase III KEYNOTE-789 study, which evaluated the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab in the treatment of adults with EGFR tyrosine kinase inhibitor–resistant, EGFR–mutated, metastatic nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA9000).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss findings from the POLARIX study, which provided the largest prospectively collected circulating tumor DNA (ctDNA) data set on patients with previously untreated diffuse large B-cell lymphoma. Achieving ctDNA-negative status was associated with improved outcomes when patients were treated with polatuzumab vedotin-piiq plus combination chemotherapy vs combination chemotherapy alone (Abstract 7523).

Advertisement

Advertisement




Advertisement